Y-L Li1, A Roalfe2, E Y-L Chu1, R Lee1, A C O Tsang3. 1. From the Division of Neuroradiology, Department of Radiology (Y.-L.L., E.Y.-L.C., R.L.), Queen Mary Hospital, Hong Kong, China. 2. Nuffield Department of Primary Care Health Sciences (A.R.), University of Oxford, Oxford, UK. 3. Division of Neurosurgery, Department of Surgery (A.C.O.T.), University of Hong Kong, Hong Kong, China acotsang@hku.hk.
Abstract
BACKGROUND: Newer flow diverters are enhanced with antithrombogenic surface modifications like the Pipeline Embolization Device with Shield Technology and the Derivo Embolization Device and are purported to facilitate deployment and reduce ischemic events. PURPOSE: Our aim was to review the safety and efficacy of surface-modified flow diverters in treating patients with cerebral aneurysms. DATA SOURCES: We used Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review and meta-analysis covering 3 major data bases and gray literature between 2014 and 2019. STUDY SELECTION: Two reviewers independently reviewed human studies of surface-modified flow diverters for eligibility based on predetermined criteria. DATA ANALYSIS: The random effects model and Freeman-Tukey arcsine transformation were used to pool efficacy outcomes (technical success, aneurysm occlusion at 6 and 12 months) and safety outcomes (mortality, morbidity, all ischemia, and serious ischemia). Subgroup analysis was performed to compare outcomes between 2 different flow diverters. DATA SYNTHESIS: Eight single-arm case series involving 911 patients and 1060 aneurysms were included. The median follow-up was 8.24 months. Pooled estimate for technical success was 99.6%, while the aneurysm occlusion at 6 and 12 months were 80.5%, and 85.6%, respectively. Pooled estimates for mortality, morbidity, total ischemia, and serious ischemia rates were 0.7%, 6.0%, 6.7%, and 1.8%, respectively. Most studies were of good quality, and no significant heterogeneity was observed. LIMITATIONS: Limitations include a retrospective, observational design in some studies; heterogeneous and underreported antiplatelet therapy; and potential performance and ecologic bias. CONCLUSIONS: Early-to-midterm safety and efficacy for surface-modified flow diverters appear comparable with older devices, especially for small, unruptured anterior circulation aneurysms. Long-term clinical data are required to further corroborate these results.
BACKGROUND: Newer flow diverters are enhanced with antithrombogenic surface modifications like the Pipeline Embolization Device with Shield Technology and the Derivo Embolization Device and are purported to facilitate deployment and reduce ischemic events. PURPOSE: Our aim was to review the safety and efficacy of surface-modified flow diverters in treating patients with cerebral aneurysms. DATA SOURCES: We used Preferred Reporting Items for Systematic Reviews and Meta-Analyses-compliant systematic review and meta-analysis covering 3 major data bases and gray literature between 2014 and 2019. STUDY SELECTION: Two reviewers independently reviewed human studies of surface-modified flow diverters for eligibility based on predetermined criteria. DATA ANALYSIS: The random effects model and Freeman-Tukey arcsine transformation were used to pool efficacy outcomes (technical success, aneurysm occlusion at 6 and 12 months) and safety outcomes (mortality, morbidity, all ischemia, and serious ischemia). Subgroup analysis was performed to compare outcomes between 2 different flow diverters. DATA SYNTHESIS: Eight single-arm case series involving 911 patients and 1060 aneurysms were included. The median follow-up was 8.24 months. Pooled estimate for technical success was 99.6%, while the aneurysm occlusion at 6 and 12 months were 80.5%, and 85.6%, respectively. Pooled estimates for mortality, morbidity, total ischemia, and serious ischemia rates were 0.7%, 6.0%, 6.7%, and 1.8%, respectively. Most studies were of good quality, and no significant heterogeneity was observed. LIMITATIONS: Limitations include a retrospective, observational design in some studies; heterogeneous and underreported antiplatelet therapy; and potential performance and ecologic bias. CONCLUSIONS: Early-to-midterm safety and efficacy for surface-modified flow diverters appear comparable with older devices, especially for small, unruptured anterior circulation aneurysms. Long-term clinical data are required to further corroborate these results.
Authors: Francesco Briganti; Giuseppe Leone; Mariano Marseglia; Giuseppe Mariniello; Ferdinando Caranci; Arturo Brunetti; Francesco Maiuri Journal: Neuroradiol J Date: 2015-08-27
Authors: Alim P Mitha; Jonathan P Mynard; John A Storwick; Zaher I Shivji; John H Wong; William Morrish Journal: Heart Lung Circ Date: 2015-02-17 Impact factor: 2.975
Authors: Olivier N Naggara; Phil M White; François Guilbert; Daniel Roy; Alain Weill; Jean Raymond Journal: Radiology Date: 2010-07-15 Impact factor: 11.105
Authors: F Cagnazzo; D Mantilla; A Rouchaud; W Brinjikji; P-H Lefevre; C Dargazanli; G Gascou; C Riquelme; P Perrini; D di Carlo; A Bonafe; V Costalat Journal: AJNR Am J Neuroradiol Date: 2018-03-15 Impact factor: 3.825
Authors: Satoshi Kiyofuji; Christopher S Graffeo; Avital Perry; Mohammad Hassan Murad; Kelly D Flemming; Giuseppe Lanzino; Leonardo Rangel-Castilla; Waleed Brinjikji Journal: J Neurointerv Surg Date: 2017-09-30 Impact factor: 5.836
Authors: Sophia Hohenstatt; Christian Ulfert; Christian Herweh; Silvia Schönenberger; Jan C Purrucker; Martin Bendszus; Markus A Möhlenbruch; Dominik F Vollherbst Journal: Clin Neuroradiol Date: 2022-09-06 Impact factor: 3.156